Pacer Advisors
ADMA icon

Pacer Advisors’s ADMA Biologics ADMA Stock Holding History

Pacer Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,645
Closed -$141K – 3808
2025
Q3 		$141K Sell
9,645
-3
-0% -$51 ﹤0.01% 2093
2025
Q2 		$176K Buy
9,648
+2,016
+26% +$41.1K ﹤0.01% 1888
2025
Q1 		$151K Sell
7,632
-30,598
-80% -$529K ﹤0.01% 1861
2024
Q4 		$656K Sell
38,230
-866
-2% -$16.3K ﹤0.01% 1517
2024
Q3 		$782K Buy
39,096
+37,504
+2,356% +$583K ﹤0.01% 1487
2024
Q2 		$17.8K Sell
1,592
-1,582
-50% -$13.3K ﹤0.01% 3451
2024
Q1 		$20.9K Buy
+3,174
New +$17.3K ﹤0.01% 3436

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Pacer Advisors's ADMA Position: Q4 2025 in Review

Pacer Advisors sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 9,645 shares — an estimated $141K sold.

Pacer Advisors first reported a position in ADMA in Q1 2024 and held it in 7 quarters. The position peaked at $782K in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Pacer Advisors reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Pacer Advisors sold 9,645 ADMA Biologics shares in Q4 2025, an estimated $141K.
  • Pacer Advisors first reported a position in ADMA Biologics in Q1 2024 and held it in 7 quarters.
  • Pacer Advisors's ADMA Biologics position peaked at $782K in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Pacer Advisors's 13F filing for Q4 2025, filed 4 Feb 2026.